Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...
Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...
MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular ...
GlobalData on MSN2d
MSD secures worldwide license for LaNova’s LM-299MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the ...
Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...
Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
(RTTNews) - Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has secured global license to develop and sell LaNova's ...
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company. Merck on Thursday said it has secured an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback